Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Less is more in the cath lab. The SINGLE-CLOSURE trial found that using just one Perclose ProGlide device for vascular closure after TAVI is noninferior to the standard two-device approach, with similarly low complication rates. The single-device strategy also offers a simpler procedure and lower costs — a win for both patients and clinicians.
Less is more in the cath lab after TAVI
The SINGLE-CLOSURE trial has delivered a clear message: one Perclose ProGlide device is enough. The first randomized study to compare single- versus double-closure strategies after transcatheter aortic valve implantation (TAVI) found that a single ProGlide device is noninferior to two devices for preventing vascular complications — and without any tradeoff in safety outcomes.
Conducted across 25 centers in China, the trial enrolled 869 patients with severe aortic stenosis. Vascular complication rates were low in both groups, with no statistically significant differences in access-related bleeding, minor vascular complications, or unplanned vascular interventions. Presenters at TCT 2026 noted the single-device approach also simplifies the procedure and reduces costs for patients.
By the Numbers
Why it matters: With two ProGlide devices currently the standard of care, these findings give clinicians a solid evidence base to simplify post-TAVI closure — cutting costs and procedural complexity without compromising patient safety.